Rifaximin Therapy in Patients of Irritable Bowel Syndrome Without Constipation Randomized Controlled Trial

Abstract

Irritable Bowel Syndrome (IBS) is a common condition affecting lives of patients across the globe. The statistics are much worse than previously thought. Studies showed that 9 -23% of the world population is suffering from IBS. Very few options are available with inadequate efficacy and a dire need for newer options. Rifaximin is one such promising drug. This study has been conducted to determine the efficacy of rifaximin therapy in IBS patients. Objective: The efficacy of rifaximin was compared with a placebo in controlling the symptoms of irritable bowel syndrome. Study design: Randomized Controlled Trial. Setting: Medicine Outpatient Clinical Department, Allied Hospital, Faisalabad. Duration of study: 27-05-2015 to 26-11-2015. Sample size: 620 (310 in each group) were enrolled in the study after fulfilling inclusion criteria. Sampling technique: Non-Probability Consecutive Sampling. Results: 620 patients were enrolled in this study. Mean age of study population was 28.31 + 6.45 (Table I). 298 (48.1%) were male and 322 (51.9%) were female. Patients were divided into group A and Group B. Group A received rifaximin and group B received placebo. In group A, improvement in IBS symptoms with Rifaximin was noted in 171 (55.1%) as compared to 90 (29.03%) in group B (p-value <0.0001). Conclusion: Rifaximin is effective in treatment of IBS without constipation. Prescribing rifaximin should be considered in treatment of IBS patients as it provides a promising treatment option which is cost effective and has fewer side effects.

Rationale, completeness and quality of evidence for the use of ursodeoxycholic acid in neonatal hyperbilirubinemia

“…Матрица оценки полноты систематических обзоров Fig.2. Matrix for evaluating the completeness of systematic reviews • в 9 исследованиях участниками являются дети с факторами риска[34][35][36][37][38][39][40][41][42], а оценка вмешательства сре-ди таких пациентов еще не освещена ни в одном систематическом обзоре.…”